HIPAA-Compliant PHI Handling in Clinical Research: A Practical Framework

AI-assisted patient screening operates at the boundary between clinical operations and health information privacy law. Eligibility screening requires accessing patient health records—protected health information under HIPAA—at the site level, routing data through external systems for algorithmic evaluation, and delivering results back to clinical staff. Each step in that data flow has compliance implications that need to be addressed before a single patient record is queried.

The good news is that the compliance framework for AI-assisted clinical trial screening is well-defined. The structure—Business Associate Agreements, data use agreements, technical safeguards, audit logging—follows established HIPAA patterns. Getting it right is primarily a matter of documentation, architecture discipline, and clear contractual coverage, not novel legal territory.

Business Associate Agreements

Any third-party vendor accessing PHI on behalf of a covered entity (the health system or site) must execute a HIPAA Business Associate Agreement (BAA) before data access begins. For clinical trial screening tools, this means a BAA between the screening vendor and each participating site or health system—not the CRO, not the sponsor, but the entity whose patients’ records are being accessed.

BAA execution is often the longest step in site activation and the step most likely to get lost in the handoff between sponsor, CRO, site, and IT teams. The CRO project manager should own BAA tracking as explicitly as they own site qualification and investigator agreements. BAA status should appear on the site activation checklist with the same visibility as IRB approval and informed consent template sign-off.

PHI Minimization and Ephemerality

The lowest-risk architecture for AI-assisted screening processes PHI ephemerally: patient records are queried, eligibility computations are performed, and output is generated—without storing PHI in the screening vendor’s systems after the session completes. The vendor retains eligibility scores and criterion-level assessments (which are not themselves PHI) but not the underlying patient records that produced them.

Ephemeral processing reduces the vendor’s HIPAA risk surface significantly: there is no PHI at rest to protect, no breach notification obligation for records the vendor no longer holds, and a simpler data retention and deletion compliance posture. CROs evaluating screening vendors should ask explicitly whether PHI is retained post-computation and what the retention policy is if any data is stored.

Technical Safeguards

HIPAA’s Technical Safeguard requirements under the Security Rule apply to ePHI at rest and in transit. The relevant standards for AI screening tools are:

• Encryption in transit: TLS 1.3 for all API calls between the site EHR and the screening platform. TLS 1.2 remains acceptable under HIPAA but should be treated as a minimum, not a target.
• Encryption at rest: AES-256 for any intermediate processing storage. For vendors using cloud infrastructure, AWS GovCloud provides FedRAMP-authorized environments with encryption at rest as a baseline.
• Access controls: Role-based access limiting data visibility to trial staff with a need to know, with authentication at least at the username/password level and ideally with multi-factor authentication for clinical staff accessing candidate results.

Audit Logging

HIPAA requires covered entities and their business associates to maintain audit logs of access to PHI. For clinical trial screening tools, this means logging every EHR query: which patient records were accessed, by which system credential, at what time, and for which trial. Those logs should be available to site compliance officers on request and retained for a minimum of six years per HIPAA records retention requirements.

Audit logs also serve an operational purpose beyond compliance: they provide an evidence trail for regulatory inspections (FDA 21 CFR Part 11 audit trail requirements apply when electronic records support clinical research decisions) and for responding to sponsor or IRB questions about the screening process.

Putting It Together

A compliant AI-assisted screening deployment requires: executed BAAs with each participating site before data access begins; ephemeral PHI processing or a documented retention and deletion policy; TLS 1.3 in transit and AES-256 at rest; role-based access controls with audit logging; and a data use agreement that specifies permitted uses of eligibility assessment outputs. None of these are novel requirements. What makes them challenging in practice is the multi-party coordination required to get them in place before enrollment begins.